Sivaraju Adithya, Tao Alice, Jadav Rakesh, Kirunda Karen N, Rampal Nishi, Kim Jennifer A, Gilmore Emily J, Hirsch Lawrence J
Comprehensive Epilepsy Center (AS, AT, RJ, KNK, NR, EJG, LJH), Department of Neurology, Yale University School of Medicine, New Haven, CT; Columbia University Medical Center (AT), New York, NY; Horizon Therapeutics (NR); Division of Neurocritical Care and Emergency Neurology (JAK, EJG), Department of Neurology, Yale University School of Medicine, New Haven, CT.
Neurol Clin Pract. 2024 Dec;14(6):e200342. doi: 10.1212/CPJ.0000000000200342. Epub 2024 Aug 16.
Patients with acute symptomatic seizures (ASyS) and acute epileptiform findings on EEG are common. They are often prescribed long-term antiseizure medications (ASMs); it is unknown whether or when this is necessary. Primary outcome was late unprovoked seizure occurrence and association with ASM taper. The secondary outcome was EEG pattern evolution over time.
This is a retrospective cohort study of patients from 2015 to 2021 with ASyS (clinical or electrographic) and/or epileptiform findings on index hospitalization EEGs who were discharged on ASMs and had subsequent follow-up including an outpatient EEG at Yale New Haven Hospital. All patients were seen in our postacute symptomatic seizure (PASS) clinic after hospital discharge. We also developed a simple predictive score, Epilepsy-PASS (EPI-PASS), using variables independently associated with seizure recurrence based on stepwise regression; each of the 3 identified variables was assigned a score of 0 (absent) or 1 (present), for a total score of 0-3.
Of 190 patients screened, 58 were excluded, leaving a final cohort of 112 patients. Twenty-four percent (27/112) patients developed a late unprovoked seizure (i.e., epilepsy). Independent predictors of epilepsy were persistence of epileptiform abnormalities on follow-up EEGs [56% developed epilepsy vs 19% without, 0.002, OR 7.18 (1.36-37.88)], clinical ASyS [32% vs 13%, = 0.002, OR 7.45 (2.31-54.36)], and cortical involvement on imaging [40% vs 11%, = 0.003, OR 7.63 (1.96-29.58)]. None of the 23 patients with none of these predictors (0 points on EPI-PASS) developed epilepsy, vs 13% with 1 predictor (EPI-PASS = 1) and 46% with 2 or 3 predictors (EPI-PASS = 2-3) at 1-year follow-up. ASM taper was not associated with seizure recurrence. Abnormal EEG findings in the index hospitalization usually resolved [54/69 (78%) patients] on subsequent EEGs.
Most patients with clinical ASyS or acute epileptiform EEG findings do not require long-term ASMs. Index hospitalization EEG findings usually resolve, but if they do not, there is a >50% chance of developing epilepsy. Other predictors of epilepsy are cortical involvement on imaging and clinical ASyS. A simple 4-point scale using these 3 predictors (EPI-PASS) may help predict the risk of developing epilepsy but requires independent validation.
急性症状性癫痫发作(ASyS)且脑电图有急性癫痫样表现的患者很常见。他们常被开具长期抗癫痫药物(ASM);尚不清楚这是否必要或何时必要。主要结局是迟发性无诱因癫痫发作的发生情况以及与ASM减量的关联。次要结局是脑电图模式随时间的演变。
这是一项回顾性队列研究,研究对象为2015年至2021年因ASyS(临床或脑电图表现)和/或在首次住院脑电图检查时有癫痫样表现且出院时服用ASM并随后在耶鲁纽黑文医院接受包括门诊脑电图检查在内的随访的患者。所有患者出院后均在我们的急性症状性癫痫发作后(PASS)诊所就诊。我们还基于逐步回归,使用与癫痫复发独立相关的变量开发了一个简单的预测评分,即癫痫-PASS(EPI-PASS);所确定的3个变量中的每一个都被赋予0分(不存在)或1分(存在),总分0至3分。
在筛选的190例患者中,58例被排除,最终队列有112例患者。24%(27/112)的患者发生了迟发性无诱因癫痫发作(即癫痫)。癫痫的独立预测因素为随访脑电图上癫痫样异常持续存在[56%发生癫痫,无异常者为19%,P = 0.002,比值比(OR)7.18(1.36 - 37.88)]、临床ASyS[32% vs 13%,P = 0.002,OR 7.45(2.31 - 54.36)]以及影像学显示皮质受累[40% vs 11%,P = 0.003,OR 7.63(1.96 - 29.58)]。在这些预测因素均无的23例患者(EPI-PASS得0分)中,无1例发生癫痫,而在1年随访时,有1个预测因素(EPI-PASS = 1)的患者中有13%发生癫痫,有2个或3个预测因素(EPI-PASS = 2 - 3)的患者中有46%发生癫痫。ASM减量与癫痫复发无关。首次住院时脑电图异常在随后的脑电图检查中通常会消失[54/69(78%)的患者]。
大多数有临床ASyS或急性癫痫样脑电图表现的患者不需要长期服用ASM。首次住院时的脑电图表现通常会消失,但如果未消失,则发生癫痫的几率>50%。癫痫的其他预测因素是影像学显示皮质受累和临床ASyS。使用这3个预测因素的简单4分制量表(EPI-PASS)可能有助于预测癫痫发生风险,但需要独立验证。